Context: Brain-derived neurotrophic factor (BDNF) haploinsufficiency is associated with hyperphagia and obesity in both animals and humans. BDNF appears to function downstream of the leptinmelanocortin signaling pathway to control energy balance. The potential role of BDNF in the etiology of the severe hyperphagia associated with PWS has not been previously explored.
remains unclear (1, 2) . Similar to nonsyndromic obesity, leptin concentrations in PWS are elevated in proportion to adiposity (3) , and immediate downstream mediators of leptin signaling also appear to be preserved because expression of the orexigenic peptides, neuropeptide Y and agouti-related protein, appear to be appropriately decreased in obese patients with PWS (4). However, possible disruption of the leptin signaling pathway further downstream of these mediators has not been explored.
Brain-derived neurotrophic factor (BDNF) is believed to function downstream of leptin-melanocortin signaling and to play an important role in regulating energy homeostasis (5) . Hypothalamic Bdnf mRNA expression is increased in the fed vs. the fasted state in normal mice (5) , and selective deletion of Bdnf in this key satiety region of the brain causes hyperphagia and obesity (6) . Heterozygous Bdnf knockout mice also exhibit hyperphagia and obesity, reversible with BDNF administration (7) . Similarly, in humans, BDNF haploinsufficiency, due to heterozygous deletion of BDNF in patients with WAGR (Wilms tumor, aniridia, genitourinary anomalies, mental retardation) syndrome (8) or disruption of BDNF expression caused by interstitial 11p inversion (9) , is associated with decreased serum BDNF concentrations, hyperphagia, and obesity. We examined serum and plasma BDNF concentrations in subjects with PWS compared with obese and lean controls to explore the potential role of BDNF in the pathophysiology of PWS.
Subjects and Methods
The study protocol was approved by the Institutional Review Board of the Duke University Medical Center. Informed written consent from the parents/guardians and assent from each child were obtained.
Subjects
Subjects with PWS were recruited from local pediatric endocrinology clinics and advertisements through PWS organizations. Control subjects were recruited from local community pediatricians and insulin resistance and obesity clinics at Duke University Medical Center. Subjects with diabetes mellitus, other chronic illnesses, or those taking investigational drugs were excluded.
Anthropometric measures
Weight was measured in subjects wearing light clothing using the same calibrated digital scale. Height was measured in triplicate using a Harpenden stadiometer. Body mass index (BMI)-Z scores were calculated using EpiInfo version 3.3.2 (Centers for Disease Control and Prevention, Atlanta, GA).
Assays
Venous whole blood was collected from subjects after a 10-h fast. Serum separator tubes (after 30-min clotting) and plasma EDTA tubes were centrifuged at 4 C for 15 min at 1500 ϫ g. Serum and plasma were stored at Ϫ70 C. Serum leptin (Linco/ Millipore, Billerica, MA) and plasma glucose and insulin were measured at the Sarah W. Stedman Center for Nutrition and Metabolism Core Laboratory, Duke University. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as [glucose (mmol/liter) ϫ insulin (mU/liter)] Ϭ 22.5 (10) . BDNF was measured in duplicate by ELISA (Quantikine; R&D Systems, Inc., Minneapolis, MN; interassay coefficient of variation, 7.6 -11.3%; intraassay coefficient of variation, 3.8 -6.2%). Before assay, all serum samples were diluted 21-fold to permit values to fall within the standard curve range. All samples were assayed simultaneously to minimize interassay variability.
Statistical analyses
Skewed data were normalized by log-transformation.
2 tests and one-way ANOVA with post hoc Tukey honestly significant difference compared groups. One-way analyses of covariance with post hoc least significant difference compared variables among groups with age, sex, and BMI-Z as covariates. Leptin and HOMA-IR were also examined as covariates for BDNF because BDNF is believed to act downstream of leptin signaling (5) and because BDNF has been associated with impaired glucose tolerance (11) . Bivariate Pearson correlation and partial correlation tests adjusting for age, sex, and BMI-Z were used to examine the association between leptin and BDNF within each group and for all subjects combined.
Results
We studied 13 subjects with PWS, 13 obese controls (OC), and 13 lean controls (LC). Subject characteristics and comparisons are shown in Table 1 . Groups were comparable for age and sex distribution. BMI-Z was comparable between PWS and OC and lower in LC. Unadjusted serum and plasma BDNF in PWS were lower compared with OC, but comparable with LC. There was overlap in BDNF values between the three groups compared (Fig. 1 ), but nearly half (six of 13 serum and four of nine plasma) of the values in the PWS children were lower than the lowest value in OC. Even after excluding the highest BDNF value in the OC group, PWS remained statistically lower (serum, P ϭ 0.047; plasma, P ϭ 0.043). We compared PWS subjects with BDNF values in the upper half (n ϭ 7) vs. the lower half (n ϭ 6) and found no differences in age (P ϭ 0.52), BMI-Z (P ϭ 0.84), or HOMA-IR (P ϭ 0.92). After correction for age, sex, and BMI-Z, adjusted serum BDNF concentrations were comparable for OC and LC, but lower in PWS compared with both OC and LC; similarly, adjusted plasma BDNF concentrations were comparable for OC and LC, but lower in PWS compared with OC ( Fig.  1) . Inclusion of leptin and HOMA-IR as covariates resulted in similar results, with lower serum BDNF in PWS compared with OC and LC (P ϭ 0.008 for overall ANOVA; P ϭ 0.008 for PWS vs. OC; P ϭ 0.01 for PWS vs. LC; P ϭ 0.17 for OC vs. LC). However, for plasma BDNF, of which fewer samples were available for analysis, overall ANOVA was nonsignificant when leptin and HOMA-IR were included in the model, with P ϭ 0.09. No significant correlations between leptin and BDNF were observed (all P Ͼ 0.22).
Discussion
In this pilot study, we observed lower serum and plasma BDNF concentrations in a small cohort of patients with PWS compared with OC. BDNF concentrations in PWS were comparable to that of lean controls, who would be appropriately expected to have lower BDNF levels than OC because BDNF is believed to play a role in regulating energy homeostasis by functioning as a satiety signal downstream of the leptin pathway (5). In fact, after correction for BMI-Z, adjusted BDNF concentrations were comparable for OC and LC, but still remained lower in PWS. Thus, our findings suggest that patients with PWS lack appropriate up-regulation of BDNF in response to adiposity.
A limitation of our study is the lack of platelet count values for our subjects. Because BDNF is stored in and released from platelets in peripheral circulation (12) , platelet levels ideally should be considered as a covariate in analyses of BDNF concentrations. Nine PWS subjects were receiving growth hormone therapy; the effect of growth hormone on BDNF is uncertain, and further studies are needed to address this. Another limitation is lack of data regarding body composition and body fat distribution, both of which could contribute to differences in metabolic parameters, including insulin sensitivity and local BDNF production in skeletal muscle (13) . Our study is also limited by the small sample sizes, and further studies are needed to confirm these findings in a larger cohort of patients with adjustment for platelet levels and body fat, but these initial observations still point to an interesting possibility that BDNF may play a role in the pathophysiology of the hyperphagia and obesity of PWS.
The primary source of BDNF in peripheral circulation is believed to be the central nervous system. Platelets serve as a reservoir, rather than as a site of BDNF production because BDNF mRNA is not detectable in either platelets or megakaryocytes (12) . Thus, peripheral BDNF concentrations may serve as a proxy of cerebral output of BDNF (11) , and therefore, the lower peripheral BDNF concentrations in our patients with PWS may reflect insufficient central BDNF production. Our observation that serum [which would contain a large portion of the BDNF content contained in platelets (12) ] and platelet-poor plasma are both decreased in PWS suggests that overall stores of BDNF as well as available free BDNF in circulation are diminished. Because BDNF appears to be an important regulator of satiety, BDNF insufficiency may be a potential cause for the disordered appetite regulation seen in PWS, which would be consistent with previous studies showing an association between low serum BDNF and hyperphagia and severe obesity (8, 9) . Furthermore, examination of changes in BDNF concentration with age could yield insight into the progression from failure-to-thrive in infancy to hyperphagia and obesity during childhood in PWS. Because leptin levels were similar between PWS and OC, a finding that has been previously observed (14) , the lack of association between BDNF and leptin was not surprising. PWS subjects appear to have lower BDNF despite having similar BMI-Z and leptin levels as OC. This would suggest that the defect in energy homeostasis lies distal to leptin production by the adipocytes-possible sites could include decreased leptin transport into the central nervous system, defects in leptin receptor signaling, proopiomelanocortin neuronal dysfunction, defects in melanocortin-4 receptor signaling, or primary defects in BDNF expression.
BDNF, acting through tropomyosin-related kinase B (TrkB), a receptor tyrosine kinase that regulates the development, differentiation, and survival of neurons and is critical in embryological nervous system development and postnatal synaptic plasticity (15) . Thus, relative BDNF reduction in PWS may potentially contribute to the complex neurobehavioral phenotype seen with this disorder, which includes variable degrees of cognitive impairment, maladaptive behaviors (obsessive-compulsiveness, temper tantrums, skin picking, rigidity of routine, high pain tolerance, attention deficit, and hyperactivity), and language difficulties (16) . In our study, approximately half of PWS subjects had BDNF concentrations that were below the lowest value observed in the OC, but there was still considerable overlap in BDNF concentrations between the PWS and control groups, suggesting interindividual variability in BDNF production. Larger studies are needed to determine whether such variations could account for differences in neurocognitive function among patients with PWS.
Interestingly, necdin, a signaling protein encoded by a gene within the PWS locus at chromosome 15q11-q12, has been shown to mediate the development and survival of sensory and autonomic neurons through facilitation of TrkA signaling (17, 18) . Due to the sequence homology of the Trk family of receptor tyrosine kinases, necdin also binds to the intracellular domain of TrkB, the receptor for BDNF (17) . Therefore, it is plausible that patients with PWS may have impaired BDNF/TrkB signaling due to necdin insufficiency. Furthermore, because BDNF and TrkB are coexpressed within the hypothalamus, diminished BDNF may be a consequence of and subsequently a perpetuating cause of reduced BDNF/TrkB signaling. Moreover, BDNF levels in PWS may be reduced due to genetic and other factors, and even mild decreases in BDNF may have a more robust effect in PWS due to the possibility that TrkB signaling may already be defective in this disorder. Of note, heterozygous Bdnf knockout mice display hyperphagia, diminished pain sensitivity, and behavioral disturbances that phenotypically resemble the abnormal behaviors of PWS (7, 19) . If larger studies confirm a connection between BDNF and PWS, therapeutic interventions aimed at modulating BDNF/ TrkB signaling may ameliorate some of the behavioral abnormalities. For example, TrkB agonists may be of benefit, as may early behavioral therapy, because early-life environmental factors have been shown in rodents to alter Bdnf promoter DNA methylation and cause lifelong changes in Bdnf expression (20) .
In summary, our observation of lower BDNF in patients with PWS compared with OC and LC sheds insight into the potential role of BDNF in the pathophysiology of the altered satiety and neurocognitive abnormalities associated with PWS.
